A Case of Hepatopulmonary Syndrome as a Complication of Metastatic Breast Cancer to the Liver
We present a patient who presented with HPS as a consequence of liver metastases and subsequently treated with chemotherapy leading to resolution of her symptoms.Case Rep Oncol 2022;15:399 –402 (Source: Case Reports in Oncology)
Source: Case Reports in Oncology - April 21, 2022 Category: Cancer & Oncology Source Type: research
Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient
We report a rare case of primary pulmonary malignant melanoma in an older adult. Immune checkpoint inhibitor therapy, as in this case, was a viable treatment option for older adults.Case Rep Oncol 2022;15:394 –398 (Source: Case Reports in Oncology)
Source: Case Reports in Oncology - April 13, 2022 Category: Cancer & Oncology Source Type: research
Poorly Differentiated Neuroendocrine Carcinoma of Unknown Primary with Metastasis to the Testis: A Case Report
Neuroendocrine neoplasms are rare epithelial neoplasms with neuroendocrine differentiation. Few cases of primary testicular poorly differentiated neuroendocrine carcinomas (PD-NECs) have been reported, and secondary testicular neoplasms are rare. A 61-year-old man with a chief complaint of left testicular swelling was referred to our hospital. An orchiectomy was performed in order to determine the pathological diagnosis. Pathological examination showed diffuse sheets of highly atypical cells that were positive for neuroendocrine markers and a Ki-67 proliferation index of 80%. The patient was diagnosed with poorly different...
Source: Case Reports in Oncology - April 8, 2022 Category: Cancer & Oncology Source Type: research
Prolonged Large Seroma Formation after Breast-Conserving Therapy
A 78-year-old obese woman with breast cancer underwent breast-conserving surgery and axillary lymph node dissection. Due to the prior exposure to long-term taxan chemotherapy for her recurrent gastric cancer, the patient did not undergo adjuvant chemotherapy and began to receive radiotherapy to both the conserved breast and supraclavicular region on the 39th day after operation. Two aspiration therapies were done to the enlarging seroma only at the initial phase of the radiotherapy. No further aspiration therapies were done to the seroma during and after radiotherapy for more than 3 months despite the undoubtable seroma fo...
Source: Case Reports in Oncology - April 4, 2022 Category: Cancer & Oncology Source Type: research
Rare < b > < i > MYH9-ROS1 < /i > < /b > Fusion Gene-Positive Lung Adenocarcinoma Showing Response to Entrectinib Treatment: A Case Study
Thec-ros oncogene 1 (ROS1) fusion gene is a rare genomic alteration detected in nearly 1 –2% of lung adenocarcinomas. The major partner genes ofROS1 includeCD74,SDC4, andEZR. Here, we report a case ofMYH9-ROS1 fusion gene-positive lung adenocarcinoma, a rareROS1 fusion gene. The patient was a woman in her 40s who was diagnosed with advanced primary lung adenocarcinoma after a thorough examination. Initial genetic testing conducted using mediastinal lymph node biopsy specimens collected by endobronchial ultrasound-guided transbronchial needle aspiration revealed no driver gene mutations, including theROS1 fusion gene. The...
Source: Case Reports in Oncology - March 31, 2022 Category: Cancer & Oncology Source Type: research
Poor Outcome due to the Plasmacytoid Variant of Urothelial Carcinoma
A 72-year-old man visited our hospital due to pollakiuria and lower abdominal pain. Urinary cytology was positive, and cystoscopy revealed diffuse edematous nonpapillary tumor. We performed transurethral biopsy, and clinical stage T3 plasmacytoid variant of urothelial carcinoma (PUC) was diagnosed. Although we planned for radical cystectomy, peritoneal dissemination and lung and pelvic lymph node metastases appeared 3 weeks after the initial visit. We also planned for chemotherapy; however, the metastases rapidly progressed, and he died 7 weeks after the biopsy. PUC is rare and shows an aggressive clinical course and poor ...
Source: Case Reports in Oncology - March 31, 2022 Category: Cancer & Oncology Source Type: research
Primary Extranodal Marginal Zone Lymphoma of the Renal Pelvis: A Case Report and Review of the Literature
Lymphomas account for approximately 5% of nonurothelial tumors of the urinary tract and develop in the bladder in 90% of cases. The most common lymphomas histologic type of this location is extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). MALT lymphoma of the upper urinary tract is casuistically rare. The current study describes a case of a 74-year-old female patient with MALT lymphoma of the renal pelvis with metastases to the retroperitoneal lymph nodes who underwent radical surgical treatment with subsequent follow-up.Case Rep Oncol 2022;15:362 –368 (Source: Case Reports in Oncology)
Source: Case Reports in Oncology - March 31, 2022 Category: Cancer & Oncology Source Type: research
Acute Exacerbation of Tracheal Obstruction and Severe Respiratory Failure after a Single Dose of 2-Gy Irradiation for Squamous Cell Lung Carcinoma: A Case Report
The patient, a 62-year-old woman, complained chiefly of cough. We planned chemoradiotherapy for squamous nonsmall cell lung cancer. A single dose of 2-Gy irradiation and no anticancer agent administration exacerbated the airway stenosis with severe respiratory failure. Urgent tracheal intubation was performed, and a tracheal stent was implanted under extracorporeal membrane oxygenation (ECMO). Because her performance status (PS) worsened from 1 to 2, we administered radiotherapy. The tumor size decreased. There was no recurrence for the next 3 months, and her PS improved to 1. Emergency tracheal intubation and tracheal ste...
Source: Case Reports in Oncology - March 30, 2022 Category: Cancer & Oncology Source Type: research
A Rare Case of Bilateral Pectoralis Major Muscle Defect and Abnormal Muscle
A 56-year-old female patient with left breast cancer presented at our hospital. Preoperative CT scan showed an isolated bilateral pectoralis major muscle defect and abnormal muscle originating from the entire sternum and inserting in the lower ribs and rectus sheath. Total mastectomy and axillary lymph node dissection were performed. We believe that this case is unique and that others like it have never been reported. If there is a defect in the pectoralis major muscle, reconstructive surgery with a tissue expander is contraindicated. Therefore, preoperative evaluation of the chest wall musculature on imaging is recommende...
Source: Case Reports in Oncology - March 30, 2022 Category: Cancer & Oncology Source Type: research
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
We report a case of CLL with CNS involvement in a 68-year-old woman who presented with a severe headache 4 years after initial diagnosis. She was started on ibrutinib, which failed to clear her CSF of malignancy. Venetoclax was then added, and this was successful in clearing her CSF. For its CNS penetration and efficacy in achieving CSF remission of CLL, we propose that venetoclax be considered as a treatment option for CLL meningitis.Case Rep Oncol 2022;15:345 –350 (Source: Case Reports in Oncology)
Source: Case Reports in Oncology - March 30, 2022 Category: Cancer & Oncology Source Type: research
Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report
Rapid tumor growth after cessation of molecularly targeted drugs, called “disease flare,” may occur and affect the prognosis of lung cancer. However, this phenomenon has never been reported in ROS proto-oncogene 1 (ROS1) fusion-positive lung adenocarcinoma. Herein, we report a disease flare in a patient with ROS1 fusion-positive lung adenocarcinoma. A 60-year-old fem ale was diagnosed with stage IVA ROS1 fusion-positive lung adenocarcinoma via bronchoscopy. Although crizotinib, an ROS1 tyrosine kinase inhibitor, achieved a partial response, a mass lesion appeared in the patient’s right kidney 12 months after starting...
Source: Case Reports in Oncology - March 30, 2022 Category: Cancer & Oncology Source Type: research
A Case of Bladder Large Cell Carcinoma with Review of the Literature
Neuroendocrine (NE) tumors of the bladder are infrequent. Among them, large cell NE tumor has been outlined only in case reports and short case series, which describes them as aggressive malignancies with dismal prognosis requiring a multidisciplinary approach. The case of an 82-year-old patient with muscle-invasive large cell NE carcinoma of the bladder associated with urothelial carcinoma in situ is presented. Despite combined treatment modality, relapse with metastatic disease was detected 12.5 months after the initial diagnosis. Thereafter, we review several published cases, and results of the collected data are compar...
Source: Case Reports in Oncology - March 29, 2022 Category: Cancer & Oncology Source Type: research
A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib
A 77-year-old man was referred to our hospital because of a hepatic tumor. Blood biochemistry showed elevated serum alfa-fetoprotein, protein induced by vitamin K absence-II, and carbohydrate antigen 19-9 levels. Gd-EOB-DTPA-enhanced magnetic resonance imaging revealed a 95-mm-sized tumor in liver S7. The tumor showed heterogeneous hyperintensity in the arterial phase, slightly washed out from the portal vein phase, and hypointensity in the hepatocellular phase. Post-enlargement segmental resection was performed, and the pathological diagnosis was combined hepatocellular cholangiocarcinoma. Seven months after surgery, mult...
Source: Case Reports in Oncology - March 29, 2022 Category: Cancer & Oncology Source Type: research
Megestrol Acetate for Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer: An Old Answer for a New Problem
We report the clinical case of a 71-year-old patient with symptomatic metastatic castration-resistant prostate cancer (mCRPC) and good PS who progressed after multiple treatments and started a hormonal therapy with megestrol acetate (MA). MA is a synthetic progestin used for treatment of mPC in 1990s since it was shown to have an antiandrogen activity. In our case, MA managed to overcome resistance to androgen receptor-targeted agents (ARTAs), getting a dramatic biochemical and radiological response and a rapid improvement of symptoms. Our clinical case shows that MA is an interesting therapeutic option especially in long-...
Source: Case Reports in Oncology - March 29, 2022 Category: Cancer & Oncology Source Type: research
Abemaciclib in Patients with End-Stage Renal Disease and Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Report of 2 Cases
This report of two women with metastatic b reast cancer suggests the potentially safe use of abemaciclib in ESRD, which should be confirmed in more extensive real-life studies.Case Rep Oncol 2022;15:305 –311 (Source: Case Reports in Oncology)
Source: Case Reports in Oncology - March 28, 2022 Category: Cancer & Oncology Source Type: research
